THE Therapeutic Goods
Administration is investigating
reports about glyceryl trinatrate
(GTN) tablets sold in Australia
under the names Anginine and
Lycinate are taking longer than
expected to dissolve under some
patients’ tongues.
The issue may affect patient
safety, and to date the reports
of longer than expected times
to dissolve and in some cases
difficulty breaking pills in half have
only related to the more recent
formulation which is available in a
circular tablet.
The affected products have not
been recalled at this stage while
the TGA continues to investigate
the issue, and the spray-based
formulation of GTN is not impacted
by the investigation.
The TGA says drinking water
before putting a tablet under the
tongue may help, and in acute
healthcare settings patients
should be closely monitored when
administering GTN tablets.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jun 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.